CORALVILLE, Iowa, May 3, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) announced today that its management has expanded its revenue outlook for its VivaSlices product currently being developed due to the increasing demand for healthcare cost reduction. VivaSlices is a software technology aimed at increasing image resolution of previous generations of MRI units saving hospitals and clinics with older equipment millions of dollars in costs related to purchasing new MRI units with enhanced image resolution capacity.
Vivakor 's Chief Executive Officer and Chief Scientific Officer, Dr. Tannin Fuja, stated, "As domestic and international healthcare systems strive to cut costs, while increasing the effectiveness of care, the need for a cost savings alternatives are receiving significant attention. In particular, we believe that the global demand for the VivaSlices products will be significant as a means of improving healthcare at a reduced cost. We estimate that the market for this technology could be in excess of $300 million annually. The estimated growth of this market will accelerate with continued global demand for cost effective healthcare."
About Vivakor, Inc.
Vivakor™ is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at www.vivakor.com.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.